Aug. 30 at 11:28 AM
$VERA Did some deep-dive weekend homework and found absolute goldmine on the biotech analysts.
• Arthur He (H.C. Wainwright) Sits in the top 350 Wall Street analysts on TipRanks with a 4.8/5-star rating, a 58% win rate, and an average return of 36.7% His biggest recorded win was on Nektar Therapeutics (
$NKTR), where his strong Buy recommendation surged from under
$2 to over
$10. He maintains a price target of
$90 for
$VERA
• Dr. Vamil Divan (Guggenheim): Former practicing physician (M.D. from SUNY Buffalo, MBA from Wharton) with an upper-tier 4.8/5-star TipRanks score, a 62% win rate.
His legendary call on Karuna Therapeutics (
$KRTX) locked in a
$288 price target while the stock traded in a range between
$65 and
$135, blasting past triple digits during phase 3 readout before Bristol Myers Squibb swooped in with a
$330 cash buyout.
Less focus on stocktwits CEO and more focus on winning more cash to plow into
$SLS ! Phase 3 readout Q3 per FDA (q3 ends Sept. 30) GLTA
